Cryo-EM structure of the AVP-vasopressin receptor 2-G signaling complex.
作者信息
Wang Lei, Xu Jun, Cao Sheng, Sun Dapeng, Liu Heng, Lu Qiuyuan, Liu Zheng, Du Yang, Zhang Cheng
机构信息
Kobilka Institute of Innovative Drug Discovery, School of Life and Health Sciences, Chinese University of Hong Kong, Shenzhen, Guangdong, 518172, China.
Department of Pharmacology and Chemical Biology, School of Medicine, University of Pittsburgh, Pittsburgh, PA, 15213, USA.
出版信息
Cell Res. 2021 Aug;31(8):932-934. doi: 10.1038/s41422-021-00483-z. Epub 2021 Mar 4.
Abstract
摘要
相似文献
1
Cryo-EM structure of the AVP-vasopressin receptor 2-G signaling complex.
Cell Res. 2021 Aug;31(8):932-934. doi: 10.1038/s41422-021-00483-z. Epub 2021 Mar 4.
2
Vasopressin receptors.
Trends Endocrinol Metab. 2000 Dec;11(10):406-10. doi: 10.1016/s1043-2760(00)00304-0.
3
Characterization of three vasopressin receptor 2 variants: an apparent polymorphism (V266A) and two loss-of-function mutations (R181C and M311V).
PLoS One. 2013 Jun 6;8(6):e65885. doi: 10.1371/journal.pone.0065885. Print 2013.
4
Author Correction: Cryo-EM structure of the AVP-vasopressin receptor 2-Gs signaling complex.
Cell Res. 2022 Oct;32(10):957. doi: 10.1038/s41422-022-00701-2.
5
Molecular pharmacology of human vasopressin receptors.
Adv Exp Med Biol. 1998;449:251-76. doi: 10.1007/978-1-4615-4871-3_34.
6
An extracellular congenital nephrogenic diabetes insipidus mutation of the vasopressin receptor reduces cell surface expression, affinity for ligand, and coupling to the Gs/adenylyl cyclase system.
Mol Endocrinol. 1994 Jul;8(7):886-94. doi: 10.1210/mend.8.7.7984150.
7
Upregulation of V(1) receptors in renal resistance vessels of rats developing genetic hypertension.
Am J Physiol Renal Physiol. 2000 Jun;278(6):F940-8. doi: 10.1152/ajprenal.2000.278.6.F940.
8
Misfolded vasopressin V2 receptors caused by extracellular point mutations entail congential nephrogenic diabetes insipidus.
Mol Cell Endocrinol. 2000 Jun;164(1-2):31-9. doi: 10.1016/s0303-7207(00)00236-7.
9
Illuminating GPCR Signaling by Cryo-EM.
Trends Cell Biol. 2018 Aug;28(8):591-594. doi: 10.1016/j.tcb.2018.06.002. Epub 2018 Jun 23.
10
Vasopressin promotes cardiomyocyte hypertrophy via the vasopressin V1A receptor in neonatal mice.
Eur J Pharmacol. 2007 Mar 22;559(2-3):89-97. doi: 10.1016/j.ejphar.2006.12.010. Epub 2006 Dec 29.
引用本文的文献
1
Membrane-domain compartmentalization of active GPCRs by β-arrestins through PtdIns(4,5)P binding.
Nat Chem Biol. 2025 Aug 6. doi: 10.1038/s41589-025-01967-4.
2
Inactive structures of the vasopressin V2 receptor reveal distinct binding modes for Tolvaptan and Mambaquaretin toxin.
Nat Commun. 2025 Apr 24;16(1):3899. doi: 10.1038/s41467-025-59114-5.
3
Molecular basis for chemokine recognition and activation of XCR1.
Proc Natl Acad Sci U S A. 2024 Nov 26;121(48):e2405732121. doi: 10.1073/pnas.2405732121. Epub 2024 Nov 20.
4
Biased activation of the vasopressin V2 receptor probed by molecular dynamics simulations, NMR and pharmacological studies.
Comput Struct Biotechnol J. 2024 Oct 24;23:3784-3799. doi: 10.1016/j.csbj.2024.10.039. eCollection 2024 Dec.
5
Structural basis of tolvaptan binding to the vasopressin V receptor.
Acta Pharmacol Sin. 2024 Nov;45(11):2441-2449. doi: 10.1038/s41401-024-01325-5. Epub 2024 Jun 20.
6
Structural and functional characterization of the endogenous agonist for orphan receptor GPR3.
Cell Res. 2024 Mar;34(3):262-265. doi: 10.1038/s41422-023-00919-8. Epub 2024 Jan 30.
7
Bringing GPCR Structural Biology to Medical Applications: Insights from Both V2 Vasopressin and Mu-Opioid Receptors.
Membranes (Basel). 2023 Jun 16;13(6):606. doi: 10.3390/membranes13060606.
8
Natural Peptide Toxins as an Option for Renewed Treatment of Type 2 Vasopressin Receptor-Related Diseases.
Biology (Basel). 2023 Apr 3;12(4):544. doi: 10.3390/biology12040544.
9
Structural and dynamic insights into supra-physiological activation and allosteric modulation of a muscarinic acetylcholine receptor.
Nat Commun. 2023 Jan 23;14(1):376. doi: 10.1038/s41467-022-35726-z.
10
G protein-coupled receptors in cochlea: Potential therapeutic targets for hearing loss.
Front Mol Neurosci. 2022 Oct 12;15:1028125. doi: 10.3389/fnmol.2022.1028125. eCollection 2022.
Zotero 插件